IonQ Clears DARPA's Final Hurdle as Wall Street Splits on the Superion Bet

IonQ advances to DARPA's Quantum Benchmarking Stage C, with up to $300M contingent on appropriations; Morgan Stanley holds at $49, B. Riley buys at $100.

IonQ has advanced to Stage C of the Defense Advanced Research Projects Agency's Quantum Benchmarking Initiative, a milestone that places the trapped-ion quantum computing specialist inside the final evaluation tier of a program designed to separate working hardware from laboratory promise. The agreement with the U.S. agency carries a potential total volume of up to $300 million and runs through 2029.

That headline figure comes with strings attached. Funding beyond the initial commitment depends on future congressional appropriations and interim decisions by agency officials, meaning the full $300 million is far from guaranteed.

A Broader Field, a Longer Timeline

DARPA's initiative is built around a single question: can quantum machines deliver economically useful compute power by 2033? The benchmark requires that the value generated by a quantum system exceed its operating costs — a bar that has yet to be cleared by any platform. IonQ is not alone in reaching the third phase. Atom Computing, Diraq and IBM also qualified, joining Microsoft and PsiQuantum, which were already participating.

For IonQ, the promotion is a starting gun rather than a finish line. Through 2029, the government agency will independently test multiple generations of the company's Superion architecture, with particular attention on the Superion 256 system, slated for customer delivery from 2027. The point of the exercise is neutral validation: federal evaluators will probe whether the hardware's architecture actually performs as its theoretical models claim.

Two Analysts, Two Very Different Price Targets

Wall Street's response has been anything but uniform. Morgan Stanley's Joseph Moore kept his Hold rating and a $49 price target, calling the Stage C entry external confirmation of the Superion design while cautioning that the real hardware tests are only now getting underway. The ambitious roadmap, he noted, still carries meaningful execution risk.

B. Riley sees far more upside, maintaining a Buy rating and a $100 target on the shares. The gap between the two views — roughly double — captures the central tension in the IonQ story: a validated architecture on one side, an unproven commercial engine on the other.

Bank of America added its own vote of confidence on September 28, initiating coverage with a Buy rating and a $60 price target. The move underscores growing interest among large financial institutions in commercially oriented quantum hardware developers. For institutional investors, the sector's rules are shifting — pure laboratory breakthroughs no longer move the needle. What matters now is credible evidence that theoretical quantum advantages can be converted into economic applications, and that is precisely the intersection IonQ is trying to occupy.

Shor's Algorithm, Quantified

On the technical front, IonQ published a full resource estimate for running Shor's algorithm on fault-tolerant systems. According to the calculations, a machine with 20,000 physical qubits could break the secp256k1 cryptographic standard in just under 26 days.

The paper tackles one of the most pressing questions in modern information technology. Shor's algorithm is the theoretical yardstick for cracking widely used encryption, and by modeling the hardware requirements in detail, IonQ has put a concrete number on what practical quantum computation at scale would demand.

Revenue Growth Meets a Billion-Dollar Cost Base

Operationally, the company is expanding quickly. Second-quarter 2026 revenue climbed 287% year over year to $80.1 million, and management is targeting full-year sales of $280 million to $290 million — a range that excludes any contribution from the SkyWater acquisition, which closed on July 31.

Backlog is building too. Contracted but undelivered performance obligations stood at roughly $485 million at the end of the second quarter. Against that sits a heavy cost structure: over the trailing twelve months, operating losses totaled about $1 billion. Whether the systems can deliver their promised performance gains in day-to-day laboratory conditions will be settled in the coming rounds of testing.

Market Reaction Stays Muted

The stock traded higher in European hours today, adding 1.8% to change hands at EUR 35.81. The prior session told a different story, with the shares slipping 4.8% to close at EUR 35.16 as investors weighed incremental technological progress against an investment horizon that stretches well beyond the current cycle.